Structural basis for the activity of drugs that inhibit phosphodiesterases

Structure

Volumn 12, Issue 12, 2004, Pages 2233-2247

  Card, Graeme L ^a   England, Bruce P ^a   Suzuki, Yoshihisa ^a   Fong, Daniel ^a   Powell, Ben ^a   Lee, Byunghun ^a   Luu, Catherine ^a   Tabrizizad, Maryam ^a   Gillette, Sam ^a   Ibrahim, Prabha N ^a   Artis, Dean R ^a   Bollag, Gideon ^a   Milburn, Michael V ^a   Kim, Sung Hou ^b   Schlessinger, Joseph ^c   Zhang, Kam Y J ^a  

^a PLEXXIKON INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOMILAST; FILAMINAST; GLUTAMINE; MESOPRAM; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PICLAMILAST; ROFLUMILAST; ROLIPRAM; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; ZARDAVERINE;

ARTICLE; BINDING AFFINITY; CATALYSIS; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; HYDROGEN BOND; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; RESPIRATORY TRACT DISEASE;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTEIN STRUCTURE, TERTIARY;

EID: 20844442458     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2004.10.004     Document Type: Article

References (52)

1. Alvarez R., Sette C., Yang D., Eglen R.M., Wilhelm R., Shelton E.R., Conti M. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol. Pharmacol. 48:1995;616-622
2. Ballard S.A., Gingell C.J., Tang K., Turner L.A., Price M.E., Naylor A.M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. 159:1998;2164-2171
3. Barnette M.S., Christensen S.B., Essayan D.M., Grous M., Prabhakar U., Rush J.A., Kagey-Sobotka A., Torphy T.J. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor. in vitro anti-inflammatory actions J. Pharmacol. Exp. Ther. 284:1998;420-426
4. Beavo J.A. Cyclic nucleotide phosphodiesterases. functional implications of multiple isoforms Physiol. Rev. 75:1995;725-748
5. Beavo J.A., Brunton L.L. Cyclic nucleotide research-still expanding after half a century. Nat. Rev. Mol. Cell Biol. 3:2002;710-718
6. Beeley, N.R.A., and Millican, T.A. (1993). December 1993. Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors. World-wide patent WO93/25517.
7. Bolger G.B., Peden A.H., Steele M.R., MacKenzie C., McEwan D.G., Wallace D.A., Huston E., Baillie G.S., Houslay M.D. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J. Biol. Chem. 278:2003;33351-33363
8. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., et al. Crystallography & NMR system. a new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 54:1998;905-921
9. Bundschuh D.S., Eltze M., Barsig J., Wollin L., Hatzelmann A., Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. 297:2001;280-290
10. Burley S.K., Petsko G.A. Aromatic-aromatic interaction. a mechanism of protein structure stabilization Science. 229:1985;23-28
11. Christensen, S.B. (1993). October 1993. Compounds useful for treating allergic and inflammatory diseases. World-wide patent WO93/19479.
12. Conti M. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol. Endocrinol. 14:2000;1317-1327
13. Conti M., Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63:1999;1-38
14. Corbin J.D., Francis S.H. Cyclic GMP phosphodiesterase-5. target of sildenafil J. Biol. Chem. 274:1999;13729-13732
15. Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. 56:2002;453-459
16. Daugan A.C., Gellibert F. November 2000. Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use. U.S. patent. 6:2000;143,746
17. Dunn P.J., Wood A.S. July 1999. Process for preparing Sildenafil. EU patent EP. 0812845B1:1999
18. Evans, P.R. (1993). Data Reduction. Proceedings of CCP4 Study Weekend. On Data Collection and Processing, pp. 114-122.
19. Flockerzi, D., Gutterer, B., Hatzelmann, A., Schudt, C., Beume, R., Kilian, U., and Wolf, H. January 1995. Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors. World-wide patent WO95/01338.
20. Francis S.H., Turko I.V., Corbin J.D. Cyclic nucleotide phosphodiesterases. relating structure and function Prog. Nucleic Acid Res. Mol. Biol. 65:2001;1-52
21. Gresser U., Gleiter C.H. Erectile dysfunction. comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature Eur. J. Med. Res. 7:2002;435-446
22. Haning H., Niewohner U., Schenke T., Es-Sayed M., Schmidt G., Lampe T., Bischoff E. Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. Bioorg. Med. Chem. Lett. 12:2002;865-868
23. Hatzelmann A., Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297:2001;267-279
24. Holton J., Alber T. Automated protein crystal structure determination using ELVES. Proc. Natl. Acad. Sci. USA. 101:2004;1537-1542
25. Houslay M.D. Adaptation in cyclic AMP signalling processes. a central role for cyclic AMP phosphodiesterases Semin. Cell Dev. Biol. 9:1998;161-167
26. Houslay M.D., Adams D.R. PDE4 cAMP phosphodiesterases. modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization Biochem. J. 370:2003;1-18
27. Huai Q., Colicelli J., Ke H. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry. 42:2003;13220-13226. a
28. Huai Q., Liu Y., Francis S.H., Corbin J.D., Ke H. Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor IBMX suggest a conformation determinant of inhibitor selectivity. J. Biol. Chem. 279:2003;13095-13101. b
29. Huai Q., Wang H., Sun Y., Kim H.Y., Liu Y., Ke H. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure (Camb). 11:2003;865-873. c
30. Huai Q., Wang H., Zhang W., Colman R.W., Robinson H., Ke H. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc. Natl. Acad. Sci. USA. 101:2004;9624-9629
31. Jin S.L., Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc. Natl. Acad. Sci. USA. 99:2002;7628-7633
32. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119
33. Laurent, H., Ottow, E., Kirsch, G., Wachtel, H., Schneider, H., Faulds, D., and Dinter, H. (1997). May 1997. Chiral methylphenyl oxazolidinones. World-wide patent WO97/15561.
34. Lee M.E., Markowitz J., Lee J.O., Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex. FEBS Lett. 530:2002;53-58
35. Leslie A.G. Integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 55:1999;1696-1702
36. Lombardo, L.J. (1992). June 1992. Oxime-carbamates and oxime-carbonates as bronchodilatorsand anti-inflammatory agents. U.S. patent 5,124,455.
37. McPhee I., Yarwood S.J., Scotland G., Huston E., Beard M.B., Ross A.H., Houslay E.S., Houslay M.D. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition. J. Biol. Chem. 274:1999;11796-11810
38. Mehats C., Andersen C.B., Filopanti M., Jin S.L., Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol. Metab. 13:2002;29-35
39. Murshudov G.N., Vagin A.A., Lebedev A., Wilson K.S., Dodson E.J. Efficient anisotropic refinement of macromolecular structures using FFT. Acta Crystallogr. D Biol. Crystallogr. 55:1999;247-255
40. Niewohner, U., Es-Sayed, M., Haning, H., Schenke, T., Schlemmer, K.H., Keldenich, J., Bischoff, E., Perzborn, E., Dembowsky, K., Serno, P., and Nowakowski, M. (1999). May 1999. 2-Phenyl-substituted imidazotriazinones as phosphodiesterase inhibitors. World-wide patent WO99/24433.
41. Porst H. IC351 (tadalafil, Cialis). update on clinical experience Int. J. Impot. Res. 14:2002;S57-S64
42. Robichaud A., Stamatiou P.B., Jin S.L., Lachance N., MacDonald D., Laliberte F., Liu S., Huang Z., Conti M., Chan C.C. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 110:2002;1045-1052
43. Rocque W.J., Tian G., Wiseman J.S., Holmes W.D., Zajac-Thompson I., Willard D.H., Patel I.R., Wisely G.B., Clay W.C., Kadwell S.H., et al. Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry. 36:1997;14250-14261
44. Rotella D.P. Phosphodiesterase 5 inhibitors. current status and potential applications Nat. Rev. Drug Discov. 1:2002;674-682
45. Scapin G., Patel S.B., Chung C., Varnerin J.P., Edmondson S.D., Mastracchio A., Parmee E.R., Singh S.B., Becker J.W., Van Der Ploeg L.H., et al. Crystal structure of human phosphodiesterase 3B. atomic basis for substrate and inhibitor specificity Biochemistry. 43:2004;6091-6100
46. Schudt C., Winder S., Muller B., Ukena D. Zardaverine as a selective inhibitor of phosphodiesterase isozymes. Biochem. Pharmacol. 42:1991;153-162
47. Souness J.E., Aldous D., Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology. 47:2000;127-162
48. Sung B.J., Yeon Hwang K., Ho Jeon Y., Lee J.I., Heo Y.S., Hwan Kim J., Moon J., Min Yoon J., Hyun Y.L., Kim E., et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 425:2003;98-102
49. Terry R., Cheung Y.F., Praestegaard M., Baillie G.S., Huston E., Gall I., Adams D.R., Houslay M.D. Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. Cell. Signal. 15:2003;955-971
50. Xu R.X., Hassell A.M., Vanderwall D., Lambert M.H., Holmes W.D., Luther M.A., Rocque W.J., Milburn M.V., Zhao Y., Ke H., Nolte R.T. Atomic structure of PDE4. insights into phosphodiesterase mechanism and specificity Science. 288:2000;1822-1825
51. Xu R.X., Rocque W.J., Lambert M.H., Vanderwall D.E., Luther M.A., Nolte R.T. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with amp 8-br-AMP, and rolipram. J. Mol. Biol. 337:2004;355-365
52. Zhang K.Y.J., Card G.L., Suzuki Y., Artis D.R., Fong D., Gillette S., Hsieh D., Neiman J., West B.L., Zhang C., et al. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol. Cell. 15:2004;279-286